Leerink Partnrs Predicts Merus’ Q3 Earnings (NASDAQ:MRUS)

Merus N.V. (NASDAQ:MRUS) – Equities researchers at Leerink Partnrs lowered their Q3 2025 EPS estimates for Merus in a research note issued to investors on Wednesday, August 6th. Leerink Partnrs analyst A. Berens now expects that the biotechnology company will earn ($1.50) per share for the quarter, down from their previous estimate of ($1.32). The consensus estimate for Merus’ current full-year earnings is ($3.85) per share. Leerink Partnrs also issued estimates for Merus’ Q4 2025 earnings at ($1.52) EPS, FY2025 earnings at ($6.63) EPS, FY2026 earnings at ($5.70) EPS and FY2027 earnings at ($5.85) EPS.

Merus (NASDAQ:MRUS) last issued its quarterly earnings data on Tuesday, August 5th. The biotechnology company reported ($2.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($1.06). The company had revenue of $8.83 million during the quarter, compared to analyst estimates of $9.77 million. Merus had a negative net margin of 685.64% and a negative return on equity of 50.28%.

MRUS has been the subject of several other reports. William Blair reaffirmed an “outperform” rating on shares of Merus in a report on Monday, April 28th. Wall Street Zen lowered shares of Merus from a “hold” rating to a “sell” rating in a research report on Sunday, July 20th. Needham & Company LLC decreased their price objective on shares of Merus from $97.00 to $96.00 and set a “buy” rating for the company in a research report on Wednesday, August 6th. BMO Capital Markets set a $110.00 target price on shares of Merus and gave the stock an “outperform” rating in a research note on Friday, May 23rd. Finally, HC Wainwright upgraded Merus to a “strong-buy” rating in a research report on Wednesday, August 6th. One equities research analyst has rated the stock with a sell rating, ten have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Merus currently has an average rating of “Moderate Buy” and an average target price of $88.50.

Merus Trading Up 0.9%

Shares of NASDAQ:MRUS opened at $64.60 on Monday. Merus has a 12-month low of $33.19 and a 12-month high of $67.59. The business has a 50 day moving average of $58.22 and a two-hundred day moving average of $48.93. The company has a market capitalization of $4.89 billion, a PE ratio of -11.75 and a beta of 1.09.

Insider Buying and Selling at Merus

In related news, COO Peter B. Silverman sold 34,000 shares of the firm’s stock in a transaction dated Friday, June 20th. The shares were sold at an average price of $52.76, for a total value of $1,793,840.00. The sale was disclosed in a document filed with the SEC, which is available through this link. In the last three months, insiders have sold 82,500 shares of company stock worth $4,586,340. 3.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Merus

A number of hedge funds have recently made changes to their positions in MRUS. GAMMA Investing LLC boosted its stake in shares of Merus by 2,153.6% in the first quarter. GAMMA Investing LLC now owns 631 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 603 shares during the last quarter. CWM LLC raised its stake in Merus by 299.0% in the 2nd quarter. CWM LLC now owns 802 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 601 shares during the last quarter. State of Wyoming purchased a new position in Merus in the 4th quarter valued at $48,000. Wells Fargo & Company MN boosted its stake in Merus by 27.3% during the 4th quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 300 shares during the last quarter. Finally, GF Fund Management CO. LTD. acquired a new stake in Merus during the 4th quarter worth $60,000. Institutional investors and hedge funds own 96.14% of the company’s stock.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.